Corrigendum to “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation–positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy” [Lung Cancer 177 (2023) 44–50]

IF 4.5 2区医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2024-07-01 DOI:10.1016/j.lungcan.2024.107852

Masayuki Takeda , Mototsugu Shimokawa , Atsushi Nakamura , Kaname Nosaki , Yasutaka Watanabe , Terufumi Kato , Daisuke Hayakawa , Hiroshi Tanaka , Toshiaki Takahashi , Masahide Oki , Motoko Tachihara , Daichi Fujimoto , Hidetoshi Hayashi , Kakuhiro Yamaguchi , Shoichiro Yamamoto , Eiji Iwama , Koichi Azuma , Kazuo Hasegawa , Nobuyuki Yamamoto , Kazuhiko Nakagawa

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对 "评估奥希替尼对接受第一代或第二代表皮生长因子受体 TKI 和铂类化疗后全身性疾病（T790M 阴性）进展的表皮生长因子受体突变阳性 NSCLC 患者疗效的 II 期研究（WJOG12819L）"的更正 [Lung Cancer 177 (2023) 44-50]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.